Biological therapy for children with inflammatory bowel disease
Part of Digestive system clinical trials.
This study tests whether a biologic therapy can help children with inflammatory bowel disease (IBD) when their disease is severe or when they're having a flare-up. The goal is to see if this treatment can reduce symptoms and improve their quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be diagnosed with inflammatory bowel disease (IBD), which includes conditions like Crohn's disease or ulcerative colitis.
- Your child's IBD must be severe from the start, or they must be currently having a relapse (flare-up).
- Your child cannot already be on a biologic medicine that is controlling their symptoms well.
- Your child must not have a known immune system problem (like a weak immune system).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study monitors levels of certain medications (infliximab, adalimumab, vedolizumab, ustekinumab) in children with inflammatory bowel disease to see if adjusting the dose helps them feel better. It aims to improve treatment outcomes.
This study compares standard treatments (like steroids or immunosuppressants) with biologic therapies (which target specific immune pathways) for children and teens with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. The goal is to see which approach works better for controlling symptoms and maintaining remission.
This study compares two biologic medicines, ustekinumab and upadacitinib, to see which works better for people with Crohn's disease that hasn't improved with other treatments. The goal is to reduce inflammation and help you feel better.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This trial is looking at children and teenagers with Crohn's disease or ulcerative colitis who are starting a biologic medicine called infliximab. It aims to learn more about how this treatment works in young patients.
This trial compares different biologic medications (adalimumab, infliximab, ustekinumab, or vedolizumab) to see how well they work after one year in people with moderate-to-severe ulcerative colitis or Crohn's disease. It aims to find which treatment is most effective for patients in Upper Egypt.
Hear when a new Effect of Drug trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.